Regulators expedite review for ALTO-101, a novel treatment for cognitive impairment in schizophrenia, a condition with no currently approved therapies.
Shares surge over 76% as the company secures Nevada Tech Hub funding and a key U.S. patent for its charging technology.
The newly formed company, which began trading on Nasdaq this week, faces intense volatility following the finalized deal and ahead of a planned reverse stock split.
Health insurer's stock rallies as it maintains financial targets despite recent Medicare Star Ratings challenges.
GM, Ford, and Stellantis shares climb on news of potential tariff exemptions for U.S. vehicles, signaling a policy shift.
Singapore-based security firm Concorde International Group sees massive trading volume without any apparent news catalyst, prompting investor caution.
The bank projects a near-term price target of $135,000 for Bitcoin, citing heavy ETF inflows and a break from historical post-halving patterns.
Government award will advance the company's non-vaccine influenza therapeutic, CD388, and onshore its manufacturing ahead of a potential pandemic.